Refine your search

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

442 Study Matches

A Phase I/II, Multicenter, Open Label, Multi Arm Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Preliminary Activity Of Idasanutlin In Combination With Either Chemotherapy Or Venetoclax In The Treatment Of Pediatric And Young Adult Patients With Relapsed/Refractory Acute Leukemias Or Solid Tumors

A study of the safety of idasanutlin for children with solid tumors and leukemias that returned or did not respond to previous treatment.
Suzanne Treadway at streadway@pennstatehealth.psu.edu or 717-531-3097
All
All
This study is NOT accepting healthy volunteers
NCT04029688
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
1-30 year of age
Have a solid tumors or leukemia that returned or did not respond to previous treatment
Exclusion Criteria:
Have a primary CNS tumor
Have uncontrolled infection
Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Defining the cellular and molecular signatures that are associated with the clinical heterogeneity of hidradenitis suppurativa

Patients with the clinical diagnosis of mild, moderate to severe Hidradenditis Suppurativa or normal healthy volunteers ages 18 and older to participate in a 1 time study visit. There is no treatment provided but we may gain information for the treatment of HS.
Amy Longenecker at alongenecker@pennstatehealth.psu.edu or 717-531-1513
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years and older
Hidradentitis Suppurativa diagnosis for 3 months
Normal skin participants
Exclusion Criteria:
Patients who are Pregnant
Normal skin participants do not have an autoimmune disease
Participants who do not want to have any of the lesion sampling performed
Skin Conditions
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

An Observational, Non-Interventional Study of Patients with Hereditary Angioedema in the United States and Canada (EMPOWER study)

Evaluate real-world effectiveness of drug in patients with hereditary angioedema (HAE). Patient reported attack diaries and patient-reported outcomes (PROs) as well as physician assessments at visits will be used to describe HAE attack rates, treatment patterns, healthcare utilization and patient quality of life.
Joshua Adams at jadams4@pennstatehealth.psu.edu or 717-531-4513
All
All
This study is NOT accepting healthy volunteers
NCT03845400
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Voluntarily able to provide consent
Diagnosis of HAE Type I or Type II
Able to use a mobile device for data collection in the study
Exclusion Criteria:
Participation in any interventional clinical trial at the time of enrollment
Unable to provide consent
Investigator believes patient is not a suitable candidate for the study
Infectious Diseases & Immune System
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

CLadribine tablets: Observational evaluation of effectIveness and patient-reported outcomes (PROs) in suboptimally Controlled patients previously taKing injectable disease-modifying drugs (DMDs) for relapsing forms of Multiple Sclerosis (RMS) (CLICK-MS)

The purpose of this study is to understand how well multiple sclerosis (MS) patients respond to a drug to help with relapsing MS (RMS), This is an oral drug called Cladribine. An observational study is research that aims to collect data over time on how a certain treatment is used and its effects, without any change to your normal care. This means that routine clinical practice is followed. Any treatment given follows your normal routine and is decided by you and your doctor. This study will not alter or interfere with the normal care you receive in any way.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03933215
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Have diagnosis of relapsing multiple sclerosis (RMS)
Have experienced suboptimal response (lack of effectiveness, intolerability, poor adherence) to injectable disease-modifying drug treatment
Exclusion Criteria:
Patients who do not have relapsing multiple sclerosis (RMS)
Patients who are doing well on injectable disease-modifying drugs
Patients who have previously been treated with cladribine in any form
Pregnant or breastfeeding women, women who plan to become pregnant or men whose partner plans to become pregnant during study
Neurology
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Associations of dietary preferences with management of HS symptoms

We will be examining the diets of people with hidradenitis suppurativa to see if they consume different amounts of foods like dairy, tomatoes, or gluten.
Melissa Butt at mbutt1@pennstatehealth.psu.edu
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
People who have a history of hidradenitis suppurativa
Seen at Penn State Health within the past year
18 years of age or older
Can read/write in English
Have access to the internet
Exclusion Criteria:
Those who do not meet inclusion criteria
Skin Conditions, Food & Nutrition
  Email this study information to me
  Contact the study team

PSCI-18-052 A Phase II Study to Evaluate the Response and Tolerability of Verzenio (Abemaciclib) in Patients with Advanced Biliary Tract Carcinoma who have Failed Prior Chemotherapy

The prognosis of patients with recurrent, late-stage inoperable, or progressed biliary tract carcinoma (BTC) is generally poor. The goal of this clinical study is to determine the effectiveness and safety of abemaciclib in patients with late-stage or progressed BTC that has failed one line of chemotherapy.
Irina Geier at igeier@pennstatehealth.psu.edu or 717-531-4300
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04003896
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Histologic or cytologic evidence of advanced or metastatic biliary tract cancer including cholangiocarcinoma (intra-hepatic or extra-hepatic bile ducts), ampullary carcinoma, and gallbladder carcinoma.
Evidence of recurrent, locally advanced, or metastatic disease.
Progressed following or intolerant to one or more line of systemic therapy.
Presence of at least 1 lesion that is measurable or evaluable using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Adequate organ function, as evidenced by the laboratory parameters noted in Study Eligibility.
Exclusion Criteria:
Ongoing or active infection requiring systemic antibiotics.
History of previous venous thromboembolic events.
Uncontrolled hypertension despite adequate therapy (i.e., systolic blood pressure higher than 150 mm Hg or diastolic blood pressure higher than 90 mm Hg found on 2 separate occasions separated by 1 week).
Diabetes mellitus and occurrence of more than 2 episodes of ketoacidosis in the 12 months prior to the first dose of study drug.
Active second malignancy other than curatively resected basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in situ carcinoma of the cervix, or other cancers with no known active disease in the 3 years prior to enrollment.
Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Design and Evaluation of a Portable Test Bed to Measure Cognitive Workload

The purpose of the experiment is to examine the effectiveness of a portable mental workload monitor. Participants will be using a game-like computer program that tests the ability to perform multiple tasks simultaneously. The experimenter will be recording performance data as well as multiple physiological indices to include a desktop eye tracker, a simple electroencephalogram (EEG), a galvanic skin response monitor, and a heart-rate monitor. The recording devices are not intrusive and should not cause discomfort.
Snehal Dhengre at sud702@psu.edu
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Be at least 18 years of age
Understand English
Have normal or normal-corrected vision
Can use standard computer monitor, a mouse, and a game controller
Exclusion Criteria:
Have visual deficiencies where the person is unable to identify the graphical images on a computer monitor from 20” away
Require use of non-standard graphical interfaces or manipulation devices
Mental & Behavioral Health
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

A Phase III Randomized Open Label Study to Compare NKTR-214 Combined with Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients with Previously Untreated Advanced Renal Cell Carcinoma (PSCI 18-122)

The purpose of the study is to compare how well the drug called NKTR-214 works when combined with the other drugs: nivolumab, sunitinib, and cabozantinib in patients with renal cell carcinoma.
Kathleen Rizzo at krizzo@pennstatehealth.psu.edu
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03729245
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years or older
Karnofsky Performance Status of at least 70
advanced or metastatic renal carcinoma
No prior systemic therapy
No active brain metastases
Exclusion Criteria:
Use of an investigational agent or an investigational device within 28 days of randomization
autoimmune disease
History of organ or tissue transplant
Prior major surgery or radiotherapy within 14 days
Any tumor invading the major blood vessels
Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Identity Fusion and "Vladimir's Choice": An Exploration of Costly Decision Making

This study will experimentally determine if individuals who identify more strongly with their political party are more likely to make decisions that cause discomfort and possible pain when faced with opposition and competition from individuals with opposing views. This goal will be accomplished in the laboratory via a game between individuals with opposing views that can be won by taking a shot of hot sauce.
Connor Somgynari at cjs72@psu.edu or 224-637-5504
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Over age 18
No food allergies
English Speaker
Exclusion Criteria:
Under age 18
Food allergies
Non-English Speakers
Food & Nutrition, Education, Mental & Behavioral Health
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

The Role of Obesity on the Phenotype and Function of Human Monocytes and their Role in Atherosclerotic Risk

We are conducting a study that is comparing the distribution of monocyte subsets (i.e. classical, intermediate and non-classical monocyte) between adults aged 55-75 with obesity/metabolic syndrome and healthy controls. The participants will have one screening visit and one study visit, and both will involve a blood draw. Each visit should take an hour or less, and the compensation for this study is $10. Lab results from screening will also be provided to participants at no cost.
Ester Oh at sxo35@psu.edu or 814-867-3720
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
55-75 years old
Non-smoker
BMI between 18.5 – 35 kg/m2
Exclusion Criteria:
Systolic BP > 160 mmHg or diastolic BP > 100 mmHg
Fasting glucose > 126 mg/dL
Use of cholesterol/lipid-lowering medications
Use of anti-hypertensive medications
Use of glucose lowering medications
Infectious Diseases & Immune System, Heart & Vascular, Prevention
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

Testing conflicting theories of semantics by constructing neuroinformatic networks of keywords using fMRI data

This is a brain imaging study that will examine how people mentally organize word meanings. Participants will perform a language task while in an MRI scanner, and their brain imaging data will be used to create networks of words that will be used to test conflicting theories of word meaning.
Dominick DiMercurio at dimercurio@psu.edu or 814-867-4341
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 18-30
Right-handed
Native speaker of English
At least a high school education
Exclusion Criteria:
History of neurogenic or psychiatric illness
Pacemaker or other metal implant
Claustrophobia
Medications that affect cognition
Language & Linguistics
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

AN OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY OF DAILY ORAL BCX7353 IN SUBJECTS WITH TYPE I AND II HEREDITARY ANGIOEDEMA

This is a clinical trial to determine the effectiveness of a daily oral medication in prevention of swelling attacks in patients with Hereditary Angioedema.
Kristina Richwine at krichwine@pennstatehealth.psu.edu or 717-531-4513
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03472040
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Type I or II HAE
Used androgen therapy for prophylaxis of HAE episodes in past 12 months
Greater than or equal 40 kg
Access to appropriate rescue medication for HAE attacks
Exclusion Criteria:
Pregnant, breastfeeding, or planned pregnancy
Prior enrollment in BCX 7353 study
Known family history of sudden cardiac death
Infectious Diseases & Immune System, Allergies
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Site for Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer (Study SWOG/NRG 1806) (PSCI#19-044)

The purpose of this study is to compare the effects, good and/or bad, of chemotherapy and radiation therapy with or without the use of atezolizumab, which is used to treat bladder cancer. The combination of chemotherapy, radiation therapy and the immunotherapy atezolizumab is considered experimental. If you decide to take part in this study, you will receive combined chemotherapy and radiation therapy which is called “chemoradiotherapy” either with or without the study drug. The chemoradiotherapy you will receive is standard of care and what your doctor thinks is best. You will receive chemoradiotherapy for up to 7 weeks. If you are assigned to the group receiving study drug, you will take the drug for up to 6 months in addition the chemoradiotherapy. Your doctor will continue to follow your condition for up to 5 years after you register to the study, even though you have finished treatment in the first year. Your doctor will watch you for side effects and to see how your cancer affects you. You will have clinic visits at 3 months from the time you stop taking treatment for the first two years and then twice a year for the third year and once a year thereafter until 5 years after you register to the study.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03775265
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Patients must have histologically proven, T2-T4a N0M0 urothelial carcinoma of the bladder within 70 days prior to randomization.
Patients must undergo radiological staging within 70 days prior to randomization. Imaging of chest, abdomen, and pelvis must be performed using CT or MRI. Patients must not have evidence of T4bN1-3 disease.
Patients with hydronephrosis are eligible if they have unilateral hydronephrosis and kidney function meets criteria specified.
Female patients of childbearing potential must have a serum pregnancy test prior to randomization.
Patients must be ≥ 18 years of age.
Exclusion Criteria:
Patient must not have received any systemic chemotherapy for their bladder cancer.
Patients must not have received prior treatment for muscle invasive bladder cancer including neoadjuvant chemotherapy for the current tumor.
Patients must not have a major surgical procedure within 28 days prior to randomization.
Patients must not have undergone prior allogeneic bone marrow transplantation or prior solid organ transplantation.
Patients must have adequate bone marrow function as evidenced by all of the following: ANC ≥ 1,500/microliter (mcL); platelets ≥ 100,000/mcL; Hemoglobin ≥ 9 g/dL. These results must be obtained within 28 days prior to randomization.
Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 3, Multi-center, Open-label, Safety Study of Oral Edaravone Administered over 48 Weeks in Subjects with Amyotrophic Lateral Sclerosis (ALS)

The purpose of this study is to test if an experimental drug called edaravone is safe and well tolerated in patients with ALS. In this study, you will receive an oral form of edaravone (a liquid solution that you will swallow). This oral formulation is considered experimental, as it has not been approved to treat ALS. The IV (intravenous) form of edaravone has been approved as a treatment for ALS. The IV form was approved in 2017 by the U.S. Food and Drug Administration (“FDA”). It is known by its commercial-brand name, Radicava, and its generic name, edaravone.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04165824
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 18-75
Forced vital capacity ≥ 70% predicted
ALS symptom onset within 3 years
Exclusion Criteria:
Undergoing treatment for cancer
Pregnancy or lactation
Hereditary fructose intolerance
Unable to take medications orally
History of hypersensitivity to edaravone
Neurology
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Investigating the impact of food form on children’s ability to compensate for energy

This study is looking at how different apple products (apple juice, apple sauce, and apple slices) might affect children's hunger and fullness. During 5 visits to our laboratory at Penn State, children will participate in a variety of games and tasks, and will eat meals and snacks with a research assistant. Children must be between the ages of 4.5-6 years old to participate in this study.
Nicole Reigh at nar5235@psu.edu
All
Younger than 18 years old
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Between age of 4.5-6.0 years-old
No food allergies
Exclusion Criteria:
Taking medication that can affect taste or appetite
Children's Health, Food & Nutrition
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

Centre County COVID-19 Data 4 Action Study

The purpose of this research is to evaluate the extent of COVID-19 risk and perceived risk among Centre County residents and students, and how those risks evolve from the time isolation guidelines were implemented through a return to normal functioning. Participants in this research will complete an electronic survey with questions about their demographic, about their exposure to COVID-19, and about how COVID-19 has affected their health and work/education. Data from this research will be used to inform Centre County planning authorities and the Pennsylvania State University about the needs of communities, including needs for information dissemination and for potentially actionable, local interventions in response to the COVID-19 pandemic.
Susan McHale at src-ssri@psu.edu
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
At least 18 years of age.
Currently living in Centre County, PA.
Expect to continue living in Centre County, PA (through at least Sept 2020)
Capable of providing your own informed consent.
Exclusion Criteria:
No additional exclusion criteria beyond those required for inclusion.
Infectious Diseases & Immune System, Men's Health, Women's Health
  Email this study information to me
  Contact the study team

PSCI-17-085 Effect of Omega-3 Fatty Acid (EPA) and its Metabolites in Combination with Tyrosine Kinase Inhibitors (TKIs) in Chronic Myeloid Leukemia (CML) in Stable Chronic Phase

The purpose of this Phase I/II study is to evaluate the safety and efficacy of the combination of tyrosine kinase inhibitors (TKIs) and an omega-3 fatty acid (like fish oil) in patients with Chronic Myeloid Leukemia (CML).
Seema Naik at snaik@pennstatehealth.psu.edu
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04006847
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Confirmed diagnosis of CML ≥ 18 months from diagnosis
Current concomitant treatment with TKI therapy (Imatinib, Dasatinib, Nilotinib or Bosutinib; excluding Ponatinib)
BCR-ABL PCR at stable molecular disease (e.g. MMR stable but not CMR) or b. Hematologic remission (HR) but no MMR
Stable molecular response defined as 2 sequential BCR-ABL levels done in the same lab with less than ½ log reduction of BCR-ABL (BA)
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score more than or equal to 3
Exclusion Criteria:
Current malignancy requiring active treatment
Active infection requiring antibiotic treatment
Known HIV, Hepatitis B, or Hepatitis C infection
Known symptomatic congestive heart failure (CHF), unstable angina or cardiac arrhythmia
Current concomitant use of NSAIDs (including Aspirin) or COX-1; a washout period of 4 weeks prior to enrollment is permitted
Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

COVID-19: Implications for Family Meals

The purpose of this study is to gather information about family meals, what they look like, and how they have changed over time since the COVID-19 pandemic. Participants will complete a confidential online survey last approximately 10-15 minutes.
Hannah Mudrick at hxm99@psu.edu or 717-948-6404
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Adults age 18 and older
Adults who live in a household with a child under the age of 18
Adult who are fluent in English
Individuals who can read and respond to written closed and open-ended survey questions electronically
Individuals who live in the United States
Exclusion Criteria:
Individuals under the age of 18
Individuals who do not reside in a household with a child under the age of 18
Individuals who are not fluent in English
Individuals with poor reading comprehension or are otherwise limited in their ability to read and respond to survey questions.
Individuals who do not currently live in the United States
Food & Nutrition
  Email this study information to me
  Contact the study team

Neurophysiological patterns of sentence processing

Spoken language can affect the brain in numerous ways. Monolingual (speaking one language) and bilingual (speaking more than one language) volunteers will complete language tasks remotely via the internet. Participants may be invited back later for an in-person study in which their brainwaves are measured by an electroencephalogram (EEG). Language tasks include listening to words and sentences, repeating words and sentences, and answering questions. Two sessions are required for the online study: a questionnaire and a Zoom meeting with a researcher.
So Yeon Chun at sfc5538@psu.edu
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Over the age of 18
Monolingual speaker of English OR
Bilingual speaker of English and at least one other language
Normal hearing
Right-handed
Exclusion Criteria:
Under the age of 18
Does not speak English
Hearing loss
History of head injury, stroke, TBI, or seizure
Language & Linguistics
  Email this study information to me
  Contact the study team

Using Social Media to Perform Parasocial Relationships with Celebrities

This research is being conducted to create a better understanding of how parasocial relationships are developed by young adults with actors, artists/musicians, and fictional characters. This research aims to understand the extent of how Tumblr users interact and follow celebrities or fictional characters and the attachment they form to them. The participants will fill out an online survey asking questions about their emotional intensity and dedication to a celebrity or fictional character as well as whether you share about them and what technology they use. Participants may skip any questions that she/he would prefer not to answer.
Courtney Smith at ces92@psu.edu
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Between 18
•25 years old
Has a Tumblr account for a celebrity or fictional character
Exclusion Criteria:
Younger than 18 years old
Older than 25 years old
Does not have a Tumblr account for a celebrity or fictional character
Men's Health, Education, Women's Health
  Email this study information to me
  Contact the study team

Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML) (PrE0905)

The purpose of this study is to compare the effectiveness of gilteritinib to midostaurin in patients receiving standard combination chemotherapy for a particular change in AML of their leukemia cells (called a mutation) in a gene called FLT3.
Lea Russell at lrussell@pennstatehealth.psu.edu or 717-531-8678
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03836209
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
AML with FLT3 mutation status (includes signal ratio)
Verified confirmation that blasts are myeloid
Verified NPM1 mutation status
Must have an ECOG performance status of 0-3
Must have adequate organ function as measured by criteria
Exclusion Criteria:
May not have M3 AML
May not have known active Central Nervous System (CNS) leukemia
Not a woman of childbearing potential (WOCBP) or who agrees to follow the contraceptive guidance
May not have a history of Long QT Syndrome
May not have evidence of uncontrolled angina, severe uncontrolled ventricular arrhythmias, electrocardiographic evidence of acute ischemia, or congestive heart failure
Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Multicenter Phase 2, Open-Label Study of Intratumoral Tavokinogene Telseplasmid (tavo, pIL-12) plus Electroporation in Combination with Intravenous Pembrolizumab in Patients with Stage III/IV Melanoma who are Progressing on either Pembrolizumab or Nivolumab Treatment (PISCES)

The purpose of this voluntary research study is to find out what effects, good and/or bad, the combination of a type of gene therapy treatment called plasmid electroporation and pembrolizumab has on your cancer.
Irina Geier at igeier@pennstatehealth.psu.edu or 717-531-8678
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03132675
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Pathologically documented unresectable melanoma, American Joint Committee on Cancer (AJCC) version 8, Stage III or IV
Subjects must be refractory to anti-PD-1 monoclonal antibodies (pembrolizumab or nivolumab either as monotherapy or in combination with other approved checkpoint inhibitors or targeted therapies according to their approved label
Resolution/improvement of anti-PD1 mAb-related AEs (including immune related AEs; irAEs) back to Grade 0-1
BRAF V600 mutation-positive melanoma could have received standard of care targeted therapy for advanced or metastatic disease
Has a performance status of 0 or 1 on the ECOG Performance Scale
Exclusion Criteria:
Subject has disease that is suitable for local therapy administered with curative intent
Clinically active CNS metastases
Subject with a diagnosis of uveal melanoma
Subject who had an allogenic tissue/solid organ transplant
Subjects with electronic pacemakers or defibrillators
Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Randomized Controlled Pilot Study of the Use of Cannabidiol in the Management of Endometriosis Pain

We are looking to conduct a study looking at the effects of cannabidiol (CBD) in patients with endometriosis. We believe that CBD will improve both pain and quality of life. The study will last a total of 12 weeks and involve several onsite visits in addition to daily pain assessments.
Amanda Chu at achu@pennstatehealth.psu.edu
Female
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04527003
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Females ages 18-45 years at the time of enrollment
Diagnosed with endometriosis by surgical diagnosis with direct visualization and/or histopathologic confirmation of endometriosis
Exclusion Criteria:
Women that are pregnant, breastfeeding or trying to conceive
Women with chronic daily opioid use ( > 14 days / month)
Women that are currently using Cannabis based products
Non-English speaking or inability to read and understand English
Pain Management, Women's Health
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) with Pembrolizumab (MK3475) in Combination with Transarterial Chemoembolization (TACE) Versus TACE in Participants with Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012)

This is a study that will compare a study drug pembrolizumab plus a study drug lenvatinib in combination with the therapy called TACE (transarterial chemoembolization) which is a way to deliver chemotherapy locally through a procedure called embolization and how that works versus placebo (or no study medications) plus TACE and how it could lead to progression-free survival (PFS).
Irina Geier at igeier@pennstatehealth.psu.edu or 717-531-8678
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04246177
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Has a diagnosis of HCC confirmed by radiology, histology, or cytology
Has HCC localized to the liver without portal vein thrombosis, and not amenable to curative treatment such as resection, ablation, or liver transplant.
Has at least one measurable HCC lesion based on RECIST 1.1,
Has an ECOG performance score of 0 to 1
Has a predicted life expectancy of >3 months.
Exclusion Criteria:
Is currently a candidate for liver transplantation.
Has had esophageal or gastric variceal bleeding within the last 6 months.
Has clinically apparent ascites on physical examination that is not controlled with medication
Has had clinically diagnosed hepatic encephalopathy in the last 6 months unresponsive to therapy.
Has clinically significant hemoptysis from any source or tumor bleeding within 2 weeks prior
Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A double-blind randomized placebo-controlled study on the analgesic properties of amiloride in exercise-induced skeletal muscle pain

To determine if the drug Amiloride will reduce exercise related muscle pain and improve exercise tolerance in healthy volunteers.
Aimee Cauffman at acauffman@pennstatehealth.psu.edu or 717-531-1617
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
healthy males and females
between 21-40 years old
any race or ethnicity
Exclusion Criteria:
Females who are pregnant or lactating
Smoker
high blood pressure
opiod use
taking amiloride or similar medication
Heart & Vascular
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Remote testing for psychophysical studies of sensory perception and cognition

The purpose of this study is (1) to understand how the brain processes sensory information and (2) how this is affected by factors like blindness or synesthesia.
Michelle Douthitt at mdouthitt@pennstatehealth.psu.edu
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Healthy adults over 18 years old
Normal or corrected-to-normal vision
No other sensory deficits
Adults who experience synesthesia
Exclusion Criteria:
Minors under the age of 18
Neurology, Language & Linguistics, Vision & Eyes
  Email this study information to me
  Contact the study team

The changes in insulin resistance and metabolic health among young, middle aged, and older adults meeting the current aerobic exercise training recommendations.

The overall purpose of this research is to evaluate the difference the national cardiorespiratory exercise recommendations have on metabolic and cardiovascular health over 6 weeks in previously sedentary young, middle aged, and older adults matched for obesity. The participants will complete moderate intensity exercise for 30 minutes per day, 5 days per week for 6 weeks. Pre- and post-intervention testing will be completed to evaluate changes in metabolic and cardiovascular health.
Nicole Gilbertson at nmg46@psu.edu or 814-949-5016
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Ages 19-24 and 45-79 years
Physically inactive
Able to walk for at least 30 minutes
Obese
Exclusion Criteria:
Currently participating in planned, structured physical activity
Lost or gained more than 10 lbs in 6 months
Females currently pregnant or breastfeeding
Currently smoking/using tobacco products or have within the past 6 months
Having signs/symptoms or diagnosed with cardiovascular, lung, kidney, metabolic, or mental health disease
Heart & Vascular, Sports Medicine, Diabetes & Hormones
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Altoona, PA

Self-Help for Stress Related to COVID-19

This is a study on internet-based self-help for stress related to the COVID-19 pandemic. College and university students who screen high on perceived stress or measures of risk for anxiety, depression, or eating disorders during the COVID-19 pandemic will be invited to participate in this study. Participants will be randomly assigned to receive access to an internet-based self-help program for stress resilience and coping with the COVID-19 pandemic or care as usual. Symptoms of stress, anxiety, depression, and eating disorders, as well as secondary outcomes, will be assessed via questionnaire at baseline (pre-randomization), one month post-randomization, and three months post-randomization.
Gavin Rackoff at gnr18@psu.edu
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Experiencing significant stress related to COVID-19 pandemic
Fluent in English
Current college or university student
Exclusion Criteria:
Unable to provide informed consent
Under 18 years of age
Not a college or university student
Not fluent in English
Mental & Behavioral Health
  Email this study information to me
  Contact the study team

Measuring motivation for alcohol use

In this study we are interested in measuring motivation for alcohol use within the context of the level of autonomy or control a person experiences for their drinking behavior. We are also interested in examining the relationship between motivation for alcohol use and physical activity, and motivation relates to alcohol use and physical activity behaviors. If your are interested in participating, please follow the link to the screening survey to determine if you are eligible: https://redcap.ctsi.psu.edu/surveys/?s=KKLWFRHEKL (if the link does not work, please copy and paste it into your browser).
Jimikaye Courtney at jimikaye@psu.edu or 814-867-2297
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
18 years or older
English fluency
Consumed at least one alcoholic beverage per week over the past 4 weeks
Exclusion Criteria:
17 years or younger
Not fluent in English
Addiction & Substance Abuse, Food & Nutrition, Prevention
  Email this study information to me
  Contact the study team

Portion Size Training in the Immersive Virtual Reality Environment

This study aims to understand how we interact with different portion sizes of food in our environment. Participants will complete a series of tasks in an Oculus virtual reality headset and complete a number of pre-and post-questionnaires.
Caitlyn Edwards at cke5143@psu.edu
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Fluent in English
Between 18-65 years of age
Free of types I or II diabetes and cardiovascular disease.
Have had no prior diagnosis of cognitive or physical disability, including ADHD, dyslexia, or epilepsy.
Must currently own or have access to a virtual reality system.
Exclusion Criteria:
Are not fluent in English.
Are outside of the ages of 18-65 years.
Have had prior diagnosis of cognitive or physical disability, including ADHD, dyslexia, or epilepsy.
Are pregnant at the time of testing.
Do not own or have access to a virtual reality system.
Food & Nutrition, Education
  Email this study information to me
  Contact the study team